Value Pathways powered by NCCN™ Pharmacoeconomic Submission Process

The Pathways Task Force will consider data that may be useful in evaluating the pharmacoeconomic impact of a treatment option for inclusion in a Value Pathway. These data may refer to either FDA approved or off label indications for drugs and biologics used for cancer treatment, or supportive care associated with the regimen.

A cover letter (maximum 2 pages) must accompany the submission and include the following information:

- Name, Company/Organization, Address, Phone, Email, Value Pathway
- Request for Pathways Task Force to consider economic review of data for a specific disease and indication.
- Specific requested placement within the Value Pathways powered by NCCN.
- Statement of whether the submitted use is included in the NCCN treatment guideline for that indication.
- Rationale for recommended change.
- Citation of pharmacoeconomic data supporting recommendation.

Information must be submitted electronically.

Please e-mail one copy of the material to msh.pathways@mckesson.com with “Submission Request” in the subject line.

The submission may be submitted at any time. You will receive confirmation of your submission. The Pathways Task Force meets monthly to review newly available data. All submissions to the Pathways Task Force are for public record and will be posted on a publicly available website.

Any questions regarding the submission process should be directed to: msh.pathways@mckesson.com. Click here to view our Frequently Asked Questions (FAQ) document.

The current Value Pathway disease groups include:

- Anal Carcinoma
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Colon Cancer
- CLL
- CML
- Esophageal Cancer
- Gastric Cancer
- Head and Neck
  - Oropharyngeal
  - Hypopharyngeal
  - Glottic
  - Supraglottic
- Hodgkin’s Lymphoma
- Melanoma
- Multiple Myeloma
- Neuroendocrine Tumor
  - GI
  - Lung
  - Pancreas
- Non-Hodgkin’s Lymphoma
  - DLBCL
  - Follicular
  - Mantle cell
- Non-Small Cell Lung Cancer
- Ovarian/Fallopian Tube/Primary Peritoneal Cancer
- Pancreatic Cancer
- Prostate Cancer
- Rectal Cancer
- Renal Cell Cancer
- Small Cell Lung Cancer